1|Page
ICH GCP FOR CCRC EXAM NEWEST 2026 ACTUAL EXAM
TEST BANK| ICH- GCP FOR CLINICAL RESEARCH
COORDINATORS (CCRC) EXAM PREP WITH 550 REAL
EXAM QUESTIONS AND CORRECT VERIFIED ANSWERS/
ALREADY GRADED A+ (MOST RECENT!!)
Define the purpose of the Investigator's Brochure? ......ANSWER......The
IB explains the rationale for the trial, the dose, dose frequency/interval,
methods of administration, and safety monitoring procedure. It also
explains the appropriate clinical management of the study subjects
during the trial
Describe the preferred style for the IB ......ANSWER......The IB should
present in a concise, simple, objective, balances, and non-promotional
form that enables a clinician or potential investigator to understand it
and form his/her own unbiased risk-benefit analysis
Who should approve the contents of the IB? ......ANSWER......Contents
of the IB should be approved by the disciplines that generated the
described data, but a medically qualified person should generally
participate in the editing
What is the relationship between type and extent of information
included in an IB and the developmental stage of the investigational
product? ......ANSWER......It is an inverse relationship. Products with
pg. 1
,2|Page
widely understood pharmacologies require much less extensive IB than
experimental products
For an investigational product that is marketed and has a widely
understood pharmacology, what alternative may exist to an IB?
......ANSWER......Under these circumstances, a basic product
information brochure, package leaflet, or labeling may be adequate so
long as it is current, comprehensive and detailed
What type of IB is required for a marketed product that is being studied
for a new drug (eg., a new indication)? ......ANSWER......The sponsor
would prepare an IB specific to the new use
How often should an IB be reviewed? ......ANSWER......The IB should be
reviewed at least annually and revised, as necessary. More frequent
reviews may be warranted depending on the developmental stage of
the product and the availability of new information
All new information should be communicated through a revised IB. True
or False ......ANSWER......False - new information of great importance
should be communicated to the investigators and possibly the IRB/IEC
prior to inclusion in the IB
Who is responsible for ensuring that the IRB/IEC has the most current
IB? ......ANSWER......The investigate is responsible for providing updated
information to the IRB/IEC
pg. 2
,3|Page
What document can be substituted for a formal IB?
......ANSWER......When a formal IB is impractical, the sponsor-
investigator should provide an expanded background information
section in the trial protocol that contains the minimum current
information described in the guideline
An IB must include a confidentiality statement. True or False
......ANSWER......False - the confidentiality statement is an optional
inclusion
What is the function of the Summary within the IB? ......ANSWER......The
Summary section highlights the significant physical, chemical,
pharmaceutical, pharmacological, toxicological, pharmacokinetic,
metabolic, and clinical data relevant to the stage of clinical
development of the investigation
What section of the IB should include a statement containing the
chemical name (and generic/trade name, if approved), a list of all active
ingredients, and the pharmacological class of the investigational
product? ......ANSWER......The introduction should contain this
information
What section of the IB should include reference to structural similarities
that the investigational drug has with other known compounds?
......ANSWER......The Physical, Chemical, and Pharmaceutical Properties
and Formulations section should include this information
pg. 3
, 4|Page
Tabular format and/or listings are preferred in the non-clinical section of
the IB. True or False ......ANSWER......True
What qualifies an investigator to conduct a study ......ANSWER......The
investigator's qualifications include education, training and experience
as well as familiarity with the appropriate use of the investigational
drug
What constitutes evidence of an investigator's qualifications to conduct
a trial ......ANSWER......Evidence of qualifications include an up-to-date
CV and/or other relevant documentation requested by the sponsor, the
IRB/IEC or the regulatory authorities
With what documents should the investigator be familiar to ensure
appropriate use of the investigational product ......ANSWER......The
investigator should be thoroughly familiar with the protocol, the current
IB, the product information, and any other information provided by the
sponsor
As long as an investigator has an experienced research coordinator, the
investigator does not need to be totally familiar with regulatory
requirements. True or False ......ANSWER......False - the investigator
should be aware of and comply with GCPs and applicable regulatory
requirement
pg. 4
ICH GCP FOR CCRC EXAM NEWEST 2026 ACTUAL EXAM
TEST BANK| ICH- GCP FOR CLINICAL RESEARCH
COORDINATORS (CCRC) EXAM PREP WITH 550 REAL
EXAM QUESTIONS AND CORRECT VERIFIED ANSWERS/
ALREADY GRADED A+ (MOST RECENT!!)
Define the purpose of the Investigator's Brochure? ......ANSWER......The
IB explains the rationale for the trial, the dose, dose frequency/interval,
methods of administration, and safety monitoring procedure. It also
explains the appropriate clinical management of the study subjects
during the trial
Describe the preferred style for the IB ......ANSWER......The IB should
present in a concise, simple, objective, balances, and non-promotional
form that enables a clinician or potential investigator to understand it
and form his/her own unbiased risk-benefit analysis
Who should approve the contents of the IB? ......ANSWER......Contents
of the IB should be approved by the disciplines that generated the
described data, but a medically qualified person should generally
participate in the editing
What is the relationship between type and extent of information
included in an IB and the developmental stage of the investigational
product? ......ANSWER......It is an inverse relationship. Products with
pg. 1
,2|Page
widely understood pharmacologies require much less extensive IB than
experimental products
For an investigational product that is marketed and has a widely
understood pharmacology, what alternative may exist to an IB?
......ANSWER......Under these circumstances, a basic product
information brochure, package leaflet, or labeling may be adequate so
long as it is current, comprehensive and detailed
What type of IB is required for a marketed product that is being studied
for a new drug (eg., a new indication)? ......ANSWER......The sponsor
would prepare an IB specific to the new use
How often should an IB be reviewed? ......ANSWER......The IB should be
reviewed at least annually and revised, as necessary. More frequent
reviews may be warranted depending on the developmental stage of
the product and the availability of new information
All new information should be communicated through a revised IB. True
or False ......ANSWER......False - new information of great importance
should be communicated to the investigators and possibly the IRB/IEC
prior to inclusion in the IB
Who is responsible for ensuring that the IRB/IEC has the most current
IB? ......ANSWER......The investigate is responsible for providing updated
information to the IRB/IEC
pg. 2
,3|Page
What document can be substituted for a formal IB?
......ANSWER......When a formal IB is impractical, the sponsor-
investigator should provide an expanded background information
section in the trial protocol that contains the minimum current
information described in the guideline
An IB must include a confidentiality statement. True or False
......ANSWER......False - the confidentiality statement is an optional
inclusion
What is the function of the Summary within the IB? ......ANSWER......The
Summary section highlights the significant physical, chemical,
pharmaceutical, pharmacological, toxicological, pharmacokinetic,
metabolic, and clinical data relevant to the stage of clinical
development of the investigation
What section of the IB should include a statement containing the
chemical name (and generic/trade name, if approved), a list of all active
ingredients, and the pharmacological class of the investigational
product? ......ANSWER......The introduction should contain this
information
What section of the IB should include reference to structural similarities
that the investigational drug has with other known compounds?
......ANSWER......The Physical, Chemical, and Pharmaceutical Properties
and Formulations section should include this information
pg. 3
, 4|Page
Tabular format and/or listings are preferred in the non-clinical section of
the IB. True or False ......ANSWER......True
What qualifies an investigator to conduct a study ......ANSWER......The
investigator's qualifications include education, training and experience
as well as familiarity with the appropriate use of the investigational
drug
What constitutes evidence of an investigator's qualifications to conduct
a trial ......ANSWER......Evidence of qualifications include an up-to-date
CV and/or other relevant documentation requested by the sponsor, the
IRB/IEC or the regulatory authorities
With what documents should the investigator be familiar to ensure
appropriate use of the investigational product ......ANSWER......The
investigator should be thoroughly familiar with the protocol, the current
IB, the product information, and any other information provided by the
sponsor
As long as an investigator has an experienced research coordinator, the
investigator does not need to be totally familiar with regulatory
requirements. True or False ......ANSWER......False - the investigator
should be aware of and comply with GCPs and applicable regulatory
requirement
pg. 4
